Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to MYNN" (ENSG00000269984) is a natural antisense long noncoding RNA transcribed from a region opposite the MYNN gene locus. This class of noncoding RNA is known as a **natural antisense transcript (NAT)**, and such molecules are widespread in the human genome. NATs can regulate the expression of their corresponding sense (protein-coding) gene through several mechanisms: transcriptional interference, chromatin remodeling, transcript stability modulation, and RNA masking[1][2][3]. Although antisense RNAs are increasingly recognized for their roles in gene regulation, the precise biological function and disease relevance of most individual NATs—including this transcript—remain unknown. They are generally not considered direct therapeutic targets, but can potentially affect cellular processes or diseases that involve their sense gene partners. If future research identifies specific regulatory or disease associations for this antisense RNA, these entries may require updating.
Not applicable/none established
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to MYNN (ENSG00000269984).